Ipsen and EpiVax have announced the completion of a collaborative project that resulted in a “stealth” version of a botulinum neurotoxin derived therapeutic. As foreign proteins, BoNTs have the potential to elicit an immune response reducing therapeutic efficacy. Ipsen is actively developing a platform of novel neurotoxin derived therapeutics, including targeted secretion inhibitors (TSI) that are opening up new therapeutic opportunities for the development of neurotoxins. EpiVax will move the program forward, continuing product development for clinical use in neuromuscular health and aesthetic treatments.

Read the full press release by clicking this link: BoNT October 2015